Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report
2024 · Journal of Pharmaceutical Health Care and Sciences · 2 citations
https://doi.org/10.1186/s40780-024-00348-8